Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus carboplatin and paclitaxel in metastatic, recurrent, or persistent cervical cancer
2014-005491-28Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, carboplatin and paclitaxel in Cervical Cancer (CC), sponsored by Roche. Primary endpoint: Incidence of GI perforation/fistula, GI-vaginal fistula and GU fistula. Started Apr 2015; status: completed.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2014-005491-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005491-28.